- Home
- BMEA vs BSBK Comparison
BMEA vs BSBK Comparison
Compare BMEA & BSBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- BSBK
- Stock Information
- Founded
- BMEA 2017
- BSBK 1893
- Country
- BMEA United States
- BSBK United States
- Employees
- BMEA N/A
- BSBK N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- BSBK Banks
- Sector
- BMEA Health Care
- BSBK Finance
- Exchange
- BMEA Nasdaq
- BSBK Nasdaq
- Market Cap
- BMEA 125.0M
- BSBK 114.0M
- IPO Year
- BMEA 2021
- BSBK N/A
- Fundamental
- Price
- BMEA $1.66
- BSBK $9.00
- Analyst Decision
- BMEA Strong Buy
- BSBK
- Analyst Count
- BMEA 8
- BSBK 0
- Target Price
- BMEA $10.63
- BSBK N/A
- AVG Volume (30 Days)
- BMEA 3.1M
- BSBK 6.2K
- Earning Date
- BMEA 10-28-2025
- BSBK 10-31-2025
- Dividend Yield
- BMEA N/A
- BSBK N/A
- EPS Growth
- BMEA N/A
- BSBK N/A
- EPS
- BMEA N/A
- BSBK N/A
- Revenue
- BMEA N/A
- BSBK $14,709,306.00
- Revenue This Year
- BMEA N/A
- BSBK N/A
- Revenue Next Year
- BMEA N/A
- BSBK N/A
- P/E Ratio
- BMEA N/A
- BSBK N/A
- Revenue Growth
- BMEA N/A
- BSBK 16.23
- 52 Week Low
- BMEA $1.29
- BSBK $6.59
- 52 Week High
- BMEA $12.85
- BSBK $9.50
- Technical
- Relative Strength Index (RSI)
- BMEA 41.51
- BSBK 46.83
- Support Level
- BMEA $1.66
- BSBK $8.79
- Resistance Level
- BMEA $2.99
- BSBK $9.29
- Average True Range (ATR)
- BMEA 0.19
- BSBK 0.22
- MACD
- BMEA -0.06
- BSBK -0.05
- Stochastic Oscillator
- BMEA 3.96
- BSBK 38.75
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About BSBK Bogota Financial Corp.
Bogota Financial Corp is a New Jersey-based bank. It offers personal and business banking services such as savings, certificates of deposits, online banking, loans, and many more. The Bank generally grants residential, commercial, and consumer loans to, and accepts deposits from customers in New Jersey.